TR200001081T2 - CDKS inhibitörleri olarak ikame edilmiş 4-amino tiyazol-2-il bileşikleri - Google Patents

CDKS inhibitörleri olarak ikame edilmiş 4-amino tiyazol-2-il bileşikleri

Info

Publication number
TR200001081T2
TR200001081T2 TR2000/01081T TR200001081T TR200001081T2 TR 200001081 T2 TR200001081 T2 TR 200001081T2 TR 2000/01081 T TR2000/01081 T TR 2000/01081T TR 200001081 T TR200001081 T TR 200001081T TR 200001081 T2 TR200001081 T2 TR 200001081T2
Authority
TR
Turkey
Prior art keywords
compounds substituted
amino thiazole
cdks inhibitors
formula
compound
Prior art date
Application number
TR2000/01081T
Other languages
English (en)
Inventor
K. M. Chong Wesley
Song Chu Shao
K. Duvadie Rohit
Li Lin
Xiao Wei
Yang Yi
Original Assignee
Agouron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc. filed Critical Agouron Pharmaceuticals, Inc.
Publication of TR200001081T2 publication Critical patent/TR200001081T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Bu bulus, CDK1, CDK2, CDK4 ce CDK6 gibi sikline bagli kinazlarin önlenmesi için, formül (I)' e aminotiyazol bilesikleri; veya formül (I)' e ait bir bilesigin farmasötik açidan kabul gören bir tuzu, veya formül (I)' e ait bir bilesigin veya bunun farmasötik açidan kabul gören bir tuzunun bir ön ilaci veya farmasötik açidan aktif bir metaboliti ile ilgilidir.
TR2000/01081T 1997-10-27 1998-10-27 CDKS inhibitörleri olarak ikame edilmiş 4-amino tiyazol-2-il bileşikleri TR200001081T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6363497P 1997-10-27 1997-10-27
US6366697P 1997-10-28 1997-10-28

Publications (1)

Publication Number Publication Date
TR200001081T2 true TR200001081T2 (tr) 2000-10-23

Family

ID=26743609

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01081T TR200001081T2 (tr) 1997-10-27 1998-10-27 CDKS inhibitörleri olarak ikame edilmiş 4-amino tiyazol-2-il bileşikleri

Country Status (34)

Country Link
US (2) US6569878B1 (tr)
EP (1) EP1056732B1 (tr)
JP (1) JP2004500304A (tr)
KR (1) KR20010082501A (tr)
CN (1) CN1158269C (tr)
AP (1) AP1445A (tr)
AT (2) ATE332896T1 (tr)
AU (1) AU738792B2 (tr)
BG (1) BG64195B1 (tr)
BR (1) BR9815200A (tr)
CA (1) CA2306082A1 (tr)
DE (2) DE69835241T2 (tr)
EA (1) EA003527B1 (tr)
EE (1) EE200000289A (tr)
ES (2) ES2267873T3 (tr)
GE (1) GEP20032896B (tr)
HR (1) HRP20000222A2 (tr)
HU (1) HUP0004512A3 (tr)
ID (1) ID24372A (tr)
IL (1) IL135574A0 (tr)
IS (1) IS5462A (tr)
LT (1) LT4855B (tr)
LV (1) LV12592B (tr)
NO (1) NO20001955L (tr)
NZ (1) NZ503788A (tr)
OA (1) OA11352A (tr)
PL (1) PL342447A1 (tr)
RO (1) RO119463B1 (tr)
SI (1) SI20324A (tr)
SK (1) SK5212000A3 (tr)
TR (1) TR200001081T2 (tr)
UA (1) UA66810C2 (tr)
WO (1) WO1999021845A2 (tr)
YU (1) YU22400A (tr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID24372A (id) * 1997-10-27 2000-07-13 Agouron Pharma SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
CA2345146C (en) * 1998-09-22 2010-02-23 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivative
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
BRPI0009721B1 (pt) 1999-04-15 2018-11-21 Bristol-Myers Squibb Holdings Ireland inibidores de tirosina quinase de proteína cíclica
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001056567A1 (en) * 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
EP1274706A1 (en) 2000-04-18 2003-01-15 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
EP1307462A2 (en) * 2000-08-09 2003-05-07 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
ES2238463T3 (es) 2000-08-18 2005-09-01 Agouron Pharmaceuticals, Inc. Hidroxiimino-fluorenos heterociclicos y uso para inhibir proteina-quinasas.
EP1712550A3 (en) * 2000-12-22 2009-07-15 Ortho-McNeil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
CN100357278C (zh) * 2000-12-22 2007-12-26 奥索-麦克尼尔药品公司 作为激酶抑制剂的取代的三唑二胺衍生物
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
ES2255621T3 (es) * 2001-06-22 2006-07-01 MERCK & CO., INC. Inhibidores de tirosina quinasa.
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
EP1724270A3 (en) 2001-07-19 2007-01-03 Pfizer Italia S.r.l. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
EP1417188A1 (en) * 2001-08-03 2004-05-12 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives
AU2003237009B2 (en) 2002-01-22 2008-10-02 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones
US6818663B2 (en) * 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
AU2003281664A1 (en) 2002-07-25 2004-02-16 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
AU2003253364B2 (en) * 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
CA2515728A1 (en) * 2003-02-12 2004-08-26 Pfizer Inc. Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives
BRPI0407618A (pt) * 2003-02-21 2006-02-21 Pfizer derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
PL1635824T3 (pl) 2003-06-03 2010-01-29 Novartis Ag 5-Członowe heterocykliczne inhibitory P-38
DK2298743T3 (da) 2003-06-26 2012-11-26 Novartis Ag p38-Kinaseinhibitorer på grundlag af en 5-leddet heterocyclisk ring
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
DK1651615T3 (da) 2003-07-29 2010-05-25 High Point Pharmaceuticals Llc Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
WO2005047504A1 (en) * 2003-11-07 2005-05-26 The Board Of Trustees Of The University Of Illinois Induction of cellular senescence by cdk4 disruption for tumor suppression and regression
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
EP1550372A1 (en) * 2003-12-24 2005-07-06 Bayer CropScience GmbH Plant growth regulation
BRPI0507271A (pt) * 2004-01-30 2007-06-26 Ab Science 2-(3-substituìda-aril)amino-4-aril-tiazóis como inibidores de tirosina cinase
US7179827B2 (en) 2004-03-31 2007-02-20 Lexicon Genetics Incorporated Thiazoles and methods of their use
US7211576B2 (en) * 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
US7423053B2 (en) * 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
US7423051B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
CA2583428A1 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
US7253285B2 (en) * 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
US7241893B2 (en) * 2004-09-17 2007-07-10 Hoffman-La Roche Inc. Thiazolinone 2-substituted quinolines
WO2006040049A1 (en) 2004-10-14 2006-04-20 F. Hoffmann-La Roche Ag Novel azaindole thiazolinones as anti-cancer agents
AU2005321091B2 (en) 2004-12-30 2012-04-12 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases
US20080312223A1 (en) 2004-12-30 2008-12-18 Astex Therapeutics Limited Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases
EP1845973B1 (en) 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
AU2006207321B2 (en) 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
US7304074B2 (en) 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
AU2006264966B2 (en) 2005-07-04 2013-02-21 High Point Pharmaceuticals, Llc Histamine H3 receptor antagonists
AU2006274733B2 (en) 2005-07-30 2010-09-16 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
US7705009B2 (en) * 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
KR101280333B1 (ko) 2006-03-28 2013-07-02 하이 포인트 파마슈티칼스, 엘엘씨 히스타민 ｈ３ 수용체 활성을 갖는 벤조티아졸
US8318927B2 (en) 2006-05-23 2012-11-27 High Point Pharmaceuticals, Llc 6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament
SI2079732T1 (sl) 2006-05-29 2012-03-30 High Point Pharmaceuticals Llc benzodioksol il ciklopropilpiperazin il piridazin njegove soli in solvati in njegova uporaba kot antagonist histaminskega receptorja H
US8153792B2 (en) * 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
RU2009140182A (ru) * 2007-05-11 2011-06-20 Ф. Хоффманн-Ля Рош Аг (Ch) Гетариланилины в качестве модуляторов для бета-амилоида
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
US9376664B2 (en) 2010-06-14 2016-06-28 The Scripps Research Institute Reprogramming of cells to a new fate
US9321737B2 (en) * 2012-02-02 2016-04-26 Senex Biotechnology Inc CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
CN102977049A (zh) * 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 一种2-氨基-4-环丙基-5-羧酸乙酯噻唑的合成方法
CA2911902A1 (en) 2013-05-07 2014-11-13 The Regents Of The University Of California Radiomitigating pharmaceutical formulations
CN104628627A (zh) * 2014-12-23 2015-05-20 安徽德信佳生物医药有限公司 一种1-boc-4-氨基哌啶的合成方法
CN106854200B (zh) * 2015-12-08 2019-05-21 上海复星星泰医药科技有限公司 色瑞替尼及其中间体的制备方法
WO2018089902A1 (en) * 2016-11-13 2018-05-17 Apogee Biotechnology Corporation Diaminothiazole compounds, compositions and methods of use
CA3048376A1 (en) 2016-12-27 2018-07-05 Riken Bmp-signal-inhibiting compound
WO2018136766A1 (en) 2017-01-19 2018-07-26 Temple University-Of The Commonwealth System Of Higher Education Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
CN113321647A (zh) 2018-06-15 2021-08-31 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN109897014A (zh) * 2019-04-17 2019-06-18 成都睿智化学研究有限公司 一种1-（取代苯基）-4-甲基哌嗪的工艺制备方法
CN114099503A (zh) * 2020-09-01 2022-03-01 乔海灵 化合物作为cyp2e1抑制剂的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3530161A (en) 1968-08-19 1970-09-22 Shell Oil Co Aromatic isothiocyanate production
BE792402A (fr) 1971-12-07 1973-06-07 Ciba Geigy Composes heterocycliques azotes et medicaments anthelminthiqueset antimicrobiens qui en contiennent
CH593806A5 (tr) 1974-11-14 1977-12-15 Ciba Geigy Ag
US4086239A (en) 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
US4649146A (en) 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
DE3804531A1 (de) 1988-02-13 1989-08-24 Bayer Ag 5-cyano-2,4-diamino-thiazol-derivate
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
US5620963A (en) 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ATE159009T1 (de) * 1991-05-10 1997-10-15 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
WO1993006123A1 (en) 1991-09-20 1993-04-01 Fred Hutchinson Cancer Research Center Human cyclin e
US5262409A (en) 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5441880A (en) 1991-11-18 1995-08-15 Cold Spring Harbor Laboratory Human cdc25 genes, encoded products and uses thereof
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
EP0640102B1 (en) 1992-04-10 2006-08-09 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
WO1994007522A1 (en) 1992-09-30 1994-04-14 Yale University Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids
US5543291A (en) 1993-01-29 1996-08-06 Dana Farber Cancer Institute Method of detecting carcinoma
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5443962A (en) 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5514571A (en) 1993-08-05 1996-05-07 University Technologies International Inc. Cyclin D1 negative regulatory activity
US5473056A (en) 1993-10-13 1995-12-05 Merck & Co., Inc. E2F-2, a novel mammalian transcription factor
US5532167A (en) 1994-01-07 1996-07-02 Beth Israel Hospital Substrate specificity of protein kinases
US5484710A (en) 1994-01-14 1996-01-16 La Jolla Cancer Research Foundation Method of down-regulating a gene linked to a P-53 responsive element
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
AU685627B2 (en) 1994-03-18 1998-01-22 Myriad Genetics, Inc. Germline mutations in the MTS gene and method for detecting predisposition to cancer at the MTS gene
US5496831A (en) 1994-05-13 1996-03-05 The General Hospital Corporation Inhibition of insulin-induced adiposis
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
US5571523A (en) 1995-03-09 1996-11-05 President And Fellows Of Harvard College Antioxidant-induced apoptosis in vascular smooth muscle cells
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
ATE236161T1 (de) 1995-11-01 2003-04-15 Novartis Pharma Gmbh Purinderivate und verfahren zu ihrer herstellung
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
TW513418B (en) 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
ID24372A (id) * 1997-10-27 2000-07-13 Agouron Pharma SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases

Also Published As

Publication number Publication date
AU738792B2 (en) 2001-09-27
ES2256968T3 (es) 2006-07-16
KR20010082501A (ko) 2001-08-30
EE200000289A (et) 2001-06-15
ID24372A (id) 2000-07-13
HRP20000222A2 (en) 2001-02-28
SK5212000A3 (en) 2001-04-09
CN1158269C (zh) 2004-07-21
DE69835241D1 (de) 2006-08-24
NO20001955D0 (no) 2000-04-14
NZ503788A (en) 2002-11-26
ATE332896T1 (de) 2006-08-15
LV12592B (en) 2001-07-20
PL342447A1 (en) 2001-06-04
AU1366499A (en) 1999-05-17
DE69833223D1 (de) 2006-04-06
LV12592A (en) 2000-12-20
DE69833223T2 (de) 2006-09-14
BR9815200A (pt) 2001-10-16
OA11352A (en) 2003-12-23
IL135574A0 (en) 2001-05-20
AP2000001795A0 (en) 2000-06-30
RO119463B1 (ro) 2004-11-30
UA66810C2 (uk) 2004-06-15
CA2306082A1 (en) 1999-05-06
WO1999021845A3 (en) 1999-08-19
IS5462A (is) 2000-04-19
SI20324A (sl) 2001-02-28
HUP0004512A3 (en) 2003-01-28
NO20001955L (no) 2000-06-16
EP1056732A2 (en) 2000-12-06
YU22400A (sh) 2003-08-29
GEP20032896B (en) 2003-02-25
HUP0004512A2 (hu) 2002-03-28
LT4855B (lt) 2001-11-26
BG64195B1 (bg) 2004-04-30
ES2267873T3 (es) 2007-03-16
CN1276789A (zh) 2000-12-13
ATE315553T1 (de) 2006-02-15
BG104478A (en) 2001-02-28
EA003527B1 (ru) 2003-06-26
US6569878B1 (en) 2003-05-27
WO1999021845A2 (en) 1999-05-06
US20030220326A1 (en) 2003-11-27
LT2000033A (en) 2001-06-25
DE69835241T2 (de) 2007-05-31
JP2004500304A (ja) 2004-01-08
EP1056732B1 (en) 2006-01-11
EA200000464A1 (ru) 2000-12-25
AP1445A (en) 2005-07-10

Similar Documents

Publication Publication Date Title
TR200001081T2 (tr) CDKS inhibitörleri olarak ikame edilmiş 4-amino tiyazol-2-il bileşikleri
BR9910810A (pt) Utilização de derivados de bisindóis indigóides
BRPI0606317A2 (pt) compostos de pirazol, uso dos mesmos e composição farmacêutica
PT1294724E (pt) Compostos pirrolo (2,3-d ) pirimidina como agentes imunosupressivos
NO20013751L (no) Purininhibitorer av cyklinavhengig kinase 2 og IkB-<alfa>
DE69617273D1 (de) Heterocyclisch substituierte cyclopentanderivate.
TR200102001T2 (tr) P38 kinaz inhibitörleri olarak sübstitüe edilmiş pirazoller
DK1278735T3 (da) 2,4-di(hetero-)arylamino(-oxy)-5-substituerede pyrimidiner som antineoplastiske midler
NO20022864L (no) Aminotiazol inhibitorer av syklin uavhengig kinase
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
EA200100105A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ОКСАЗОЛОВ И ТИАЗОЛОВ В КАЧЕСТВЕ АКТИВАТОРОВ hPPAR ГАММА и hPPAR АЛЬФА
DE60039059D1 (de) Triazin-kinase-hemmer
ATE251160T1 (de) Purin-derivative inhibitoren der tyrosi-protein kinase syk
WO1999061444A3 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
MXPA05007352A (es) Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion.
BR1100931A (pt) Compostos derivados de aril-heteroaril carbinóis, processos para a preparação dos compostos, composições farmacêuticas, e, uso dos compostos derivados de aril-heteroaril carbinóis
UY25857A1 (es) 4-alquenil (y alquinil) oxindoles los cuales inhiben las quinasas dependientes de ciclina (cdks)
BRPI0407841A (pt) inibidores heterocìclicos de quinase
WO2003028721A3 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
DE60320849D1 (de) Anti-angiogenetische arzneimittel
BR9813719A (pt) Agentes terapêuticos
EP1215208A3 (en) 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
LV12374A (lv) (4R,5S,6S,7R)-Heksahidro-1-(5-(3-aminoindazol)metil)-3-butil-5,6-dioksi-4,7-bis(fenilmetil)-2H-1,3-diazepin-2-ons si savienojuma iegusana un ka HIV proteazes inhibitora pielietojums